Trials / Recruiting
RecruitingNCT06440330
Define Predictors for Posttransplant Diabetes Mellitus Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 330 (estimated)
- Sponsor
- University Hospital, Antwerp · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary aim of this prospective, multicentre study is to develop an accurate and convenient tool to predict the risk of PTDM at 3 months post-transplant, based on information on the day of transplantation (day 0). In order to create such model, we will start by identifying individual predictor variables at the day of transplantation and subsequently explore the optimal combination of these predictors in multivariable models. Secondary objectives include: * Compare the performance of the model based on predictor variables at day 0 with existing models for prediction of PTDM (Chakkera, San Antonio Diabetes Prediction Model and Framingham Offspring Study Diabetes Mellitus algorithm) * Explore the glucose level evolution during the first 2 weeks after transplantation using continuous glucose monitoring, and its relationship with baseline patient characteristics and immunosuppressant drug use. * Evaluate the added value of incorporating information on glucose levels in the first and second weeks post-transplant to improve the PTDM prediction model. * Identify predictors for early post-transplant hyperglycemia (first 2 weeks post-transplantation) * Explore the correlation between early post-transplant hyperglycemia (fasting glycemia, pre-dinner glycemia) and PTDM at 3 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | continuous glucose monitoring | continuous glucose monitoring will be used during the first 14 days post-transplantation |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
- First posted
- 2024-06-03
- Last updated
- 2024-06-03
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06440330. Inclusion in this directory is not an endorsement.